enGene Therapeutics

CompanyUnited States

enGene Therapeutics develops one asset, preclinical (detalimogene voraplasmid in bcg-unresponsive high-risk non-muscle-invasive bladder cancer). Mostly gene therapy; based in the United States.

1
Asset
Furthest stage: Preclinical; 0
Trials: 1
Signal

Pipeline

1

detalimogene voraplasmid
Non-viral gene delivery promotes local interferon alpha-2b expression to induce antitumor immune activity in the bladder.
Preclinical, Gene therapy, bcg-unresponsive high-risk non-muscle-invasive bladder cancer

Full company profiles: pipeline, trials, funding and people.

In the full profile

Signals2